Urodynamix Technologies Ltd. Announces Cross of 1,480,000 Common Shares
September 29 2009 - 8:00AM
Marketwired
Urodynamix Technologies Ltd. (TSX VENTURE: URO) today announced
that a cross of 1,480,000 common shares has been effected through
Canaccord Capital Inc. at a sales price of $0.05 per common share.
The traded shares were sold by Barry Allen, President and CEO of
Urodynamix Technologies Ltd. who also purchased 2,782,450 common
shares at a price of $0.05 per common share through the $1.5
million non-brokered private placement for 30,000,000 common shares
that closed on September 25, 2009. All of the shares issued by the
Company pursuant to the non-brokered private placement are subject
to a 4-month resale restriction and the Company will pay a
commission of up to 7.5% on sales of common shares to third
parties.
About Urodynamix Technologies Ltd.
Urodynamix Technologies is a Canadian medical device company
developing and commercializing non-invasive medical technology
based on proprietary applications of near-infrared spectroscopy
(NIRS). The Company is currently focused on products that aid in
the diagnosis and treatment of urinary incontinence, lower urinary
tract symptoms, erectile dysfunction, prostate cancer, benign
prostatic hyperplasia, and traumatic increases in intra-abdominal
pressure that cause abdominal compartment syndrome. Urodynamix's
breakthrough medical technology has the potential to beneficially
affect more than 200 million people worldwide.
Certain information contained in this press release may be
forward-looking and is subject to unknown risks, which could cause
actual results to differ materially from those set forth or implied
herein. Although the Company believes that the expectations
reflected in such forward-looking statements are reasonable, it can
give no assurance that such expectations will prove correct.
The TSX Venture Exchange has not reviewed and does not accept
responsibility for the adequacy or accuracy of this release.
Contacts: Urodynamix Technologies Ltd. Jonathan Jackson Chief
Financial Officer (604) 613-6116 Email: jjackson@urodynamix.com
Website: www.urodynamix.com
Urodynamix Technologies Ltd. (TSXV:URO)
Historical Stock Chart
From Jul 2024 to Aug 2024
Urodynamix Technologies Ltd. (TSXV:URO)
Historical Stock Chart
From Aug 2023 to Aug 2024
Real-Time news about Urodynamix Technologies Ltd. (TSX Venture Exchange): 0 recent articles
More Urodynamix Technologies Ltd. News Articles